Trial Outcomes & Findings for Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study (NCT NCT04791917)
NCT ID: NCT04791917
Last Updated: 2023-07-27
Results Overview
Changes in breakpoint of alcohol demand, assessed using the Alcohol Purchase Task. Breakpoint indicates the drink price at which participants report no alcohol consumption. Values represent difference scores derived from breakpoint values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
51 participants
Primary outcome timeframe
48 hours after exercise
Results posted on
2023-07-27
Participant Flow
Participant milestones
| Measure |
Delayed Onset Muscle Soreness Induction
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|
|
Overall Study
STARTED
|
26
|
25
|
|
Overall Study
COMPLETED
|
26
|
25
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Baseline characteristics by cohort
| Measure |
Delayed Onset Muscle Soreness Induction
n=26 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction
n=25 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Total
n=51 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Pain-related Negative Affect
|
139.46 total score
STANDARD_DEVIATION 90.40 • n=99 Participants
|
140.36 total score
STANDARD_DEVIATION 103.37 • n=107 Participants
|
139.90 total score
STANDARD_DEVIATION 96.00 • n=206 Participants
|
|
Age, Continuous
|
24.77 years
STANDARD_DEVIATION 7.46 • n=99 Participants
|
29.48 years
STANDARD_DEVIATION 11.81 • n=107 Participants
|
27.08 years
STANDARD_DEVIATION 10.02 • n=206 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
29 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
11 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
22 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
20 Participants
n=99 Participants
|
20 Participants
n=107 Participants
|
40 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
10 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
21 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
16 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
30 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
26 Participants
n=99 Participants
|
25 Participants
n=107 Participants
|
51 Participants
n=206 Participants
|
|
Employment
Employed
|
14 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
24 Participants
n=206 Participants
|
|
Employment
Unemployed
|
12 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
27 Participants
n=206 Participants
|
|
PHQ-9
|
4.35 units on a scale
STANDARD_DEVIATION 3.17 • n=99 Participants
|
4.92 units on a scale
STANDARD_DEVIATION 4.34 • n=107 Participants
|
4.63 units on a scale
STANDARD_DEVIATION 3.76 • n=206 Participants
|
|
GAD-7
|
5.00 units on a scale
STANDARD_DEVIATION 4.52 • n=99 Participants
|
4.12 units on a scale
STANDARD_DEVIATION 3.43 • n=107 Participants
|
4.57 units on a scale
STANDARD_DEVIATION 4.01 • n=206 Participants
|
|
Negative Urgency
|
8.35 units on UPPS-P subscale
STANDARD_DEVIATION 2.95 • n=99 Participants
|
8.67 units on UPPS-P subscale
STANDARD_DEVIATION 2.82 • n=107 Participants
|
8.50 units on UPPS-P subscale
STANDARD_DEVIATION 2.87 • n=206 Participants
|
|
Alcohol Use Urge
|
19.96 visual analog scale units
STANDARD_DEVIATION 24.51 • n=99 Participants
|
40.64 visual analog scale units
STANDARD_DEVIATION 28.05 • n=107 Participants
|
29.44 visual analog scale units
STANDARD_DEVIATION 27.92 • n=206 Participants
|
|
Cannabis Use Urge
|
44.81 visual analog scale units
STANDARD_DEVIATION 34.02 • n=99 Participants
|
67.58 visual analog scale units
STANDARD_DEVIATION 23.99 • n=107 Participants
|
55.74 visual analog scale units
STANDARD_DEVIATION 31.51 • n=206 Participants
|
|
History of Alcohol Self-Medication
|
57.28 visual analog scale units
STANDARD_DEVIATION 54.59 • n=99 Participants
|
73.96 visual analog scale units
STANDARD_DEVIATION 45.19 • n=107 Participants
|
65.62 visual analog scale units
STANDARD_DEVIATION 50.31 • n=206 Participants
|
|
History of Cannabis Self-Medication
|
107.31 visual analog scale units
STANDARD_DEVIATION 60.77 • n=99 Participants
|
114.08 visual analog scale units
STANDARD_DEVIATION 58.64 • n=107 Participants
|
110.63 visual analog scale units
STANDARD_DEVIATION 59.24 • n=206 Participants
|
|
Alcohol Expectancy VAS 1
|
37.08 visual analog scale units
STANDARD_DEVIATION 29.29 • n=99 Participants
|
44.72 visual analog scale units
STANDARD_DEVIATION 26.33 • n=107 Participants
|
40.90 visual analog scale units
STANDARD_DEVIATION 27.83 • n=206 Participants
|
|
Alcohol Expectancy VAS 2
|
25.81 visual analog scale units
STANDARD_DEVIATION 18.31 • n=99 Participants
|
28.20 visual analog scale units
STANDARD_DEVIATION 16.89 • n=107 Participants
|
26.98 visual analog scale units
STANDARD_DEVIATION 17.53 • n=206 Participants
|
|
Cannabis Expectancy VAS 1
|
62.35 visual analog scale units
STANDARD_DEVIATION 28.27 • n=99 Participants
|
71.76 visual analog scale units
STANDARD_DEVIATION 18.82 • n=107 Participants
|
66.96 visual analog scale units
STANDARD_DEVIATION 24.34 • n=206 Participants
|
|
Cannabis Expectancy VAS 2
|
38.32 visual analog scale units
STANDARD_DEVIATION 26.93 • n=99 Participants
|
38.08 visual analog scale units
STANDARD_DEVIATION 26.71 • n=107 Participants
|
38.20 visual analog scale units
STANDARD_DEVIATION 26.54 • n=206 Participants
|
|
AUDIT Total Score
|
10.54 units on a scale
STANDARD_DEVIATION 4.52 • n=99 Participants
|
11.36 units on a scale
STANDARD_DEVIATION 5.99 • n=107 Participants
|
10.94 units on a scale
STANDARD_DEVIATION 5.26 • n=206 Participants
|
|
CUDIT Total Score
|
11.77 units on a scale
STANDARD_DEVIATION 4.92 • n=99 Participants
|
14.57 units on a scale
STANDARD_DEVIATION 7.12 • n=107 Participants
|
13.14 units on a scale
STANDARD_DEVIATION 6.20 • n=206 Participants
|
|
ASSIST Cannabis Risk Score
|
13.62 units on a scale
STANDARD_DEVIATION 7.23 • n=99 Participants
|
15.28 units on a scale
STANDARD_DEVIATION 6.57 • n=107 Participants
|
14.43 units on a scale
STANDARD_DEVIATION 6.90 • n=206 Participants
|
|
Alcohol Use Frequency
2 to 3 times a week
|
21 Participants
n=99 Participants
|
18 Participants
n=107 Participants
|
39 Participants
n=206 Participants
|
|
Alcohol Use Frequency
4 or more times a week
|
5 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Drinks Per Drinking Day
1 or 2
|
7 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
18 Participants
n=206 Participants
|
|
Drinks Per Drinking Day
3 or 4
|
9 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Drinks Per Drinking Day
5 or 6
|
8 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Drinks Per Drinking Day
7 to 9
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Cannabis Use Frequency
Once a week
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Cannabis Use Frequency
Twice a week
|
9 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Cannabis Use Frequency
3-4 times a week
|
7 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
16 Participants
n=206 Participants
|
|
Cannabis Use Frequency
5-6 times a week
|
1 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Cannabis Use Frequency
Once a day
|
4 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Cannabis Use Frequency
More than once a day
|
4 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
1-3 months
|
3 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
3-6 months
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
6-9 months
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
9-12 months
|
3 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
1-2 years
|
7 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
13 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
2-3 years
|
5 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
3-5 years
|
1 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
5-10 years
|
3 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
10-15 years
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Duration of Cannabis Use at Current Frequency
More than 20 years
|
0 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Primary Method Used to Ingest Cannabis
Joints
|
6 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
16 Participants
n=206 Participants
|
|
Primary Method Used to Ingest Cannabis
Blunts
|
5 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Primary Method Used to Ingest Cannabis
Hand pipe
|
6 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
|
Primary Method Used to Ingest Cannabis
Bong/Water Pipe
|
6 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Primary Method Used to Ingest Cannabis
Vaporizer
|
3 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Primary Method Used to Ingest Cannabis
Edibles
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Primary Method Used to Ingest Cannabis
Other
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Primary Form of Cannabis Used
Flower/Herbal Cannabis
|
24 Participants
n=99 Participants
|
23 Participants
n=107 Participants
|
47 Participants
n=206 Participants
|
|
Primary Form of Cannabis Used
Concentrates (e.g., oil, wax, shatter, hash, dabs)
|
2 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Primary Form of Cannabis Used
Edibles
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Frequency of Simultaneous Alcohol and Cannabis Use
|
53 visual analog scale units
STANDARD_DEVIATION 19.17 • n=99 Participants
|
62.32 visual analog scale units
STANDARD_DEVIATION 21.26 • n=107 Participants
|
57.76 visual analog scale units
STANDARD_DEVIATION 20.60 • n=206 Participants
|
|
Amount Spent on Alcohol in Past Month
|
84.77 dollars
STANDARD_DEVIATION 79.49 • n=99 Participants
|
110.48 dollars
STANDARD_DEVIATION 84.08 • n=107 Participants
|
97.33 dollars
STANDARD_DEVIATION 81.82 • n=206 Participants
|
|
Amount Spent on Cannabis in Past Month
|
88.86 dollars
STANDARD_DEVIATION 90.10 • n=99 Participants
|
102.62 dollars
STANDARD_DEVIATION 113.91 • n=107 Participants
|
95.58 dollars
STANDARD_DEVIATION 101.43 • n=206 Participants
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in breakpoint of alcohol demand, assessed using the Alcohol Purchase Task. Breakpoint indicates the drink price at which participants report no alcohol consumption. Values represent difference scores derived from breakpoint values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Alcohol Demand: Breakpoint
|
-6.00 dollars/drink
Standard Deviation 7.62
|
-2.07 dollars/drink
Standard Deviation 5.61
|
-1.81 dollars/drink
Standard Deviation 4.45
|
-1.09 dollars/drink
Standard Deviation 8.51
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in Omax, assessed using the Alcohol Purchase Task. Omax reflects the highest total amount in dollars that a participant would spend on alcohol-containing beverages. Values represent difference scores derived from log-transformed Omax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Alcohol Demand: Omax
|
-.255 (log)dollars
Standard Deviation .497
|
-.089 (log)dollars
Standard Deviation .20
|
-.03 (log)dollars
Standard Deviation .40
|
-.168 (log)dollars
Standard Deviation .36
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in Pmax, assessed using the Alcohol Purchase Task. Pmax reflects the price point at which demand for alcohol becomes elastic (i.e., declines in response to increasing price). Values represent difference scores derived from log-transformed Pmax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Alcohol Demand: Pmax
|
-.19 log(dollars/drink)
Standard Deviation .36
|
-.080 log(dollars/drink)
Standard Deviation .24
|
.0054 log(dollars/drink)
Standard Deviation .24
|
-.11 log(dollars/drink)
Standard Deviation .299
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in Essential Value, assessed using the Alcohol Purchase Task. Essential Value represents the reinforcing efficacy of alcohol, such that higher Essential Value indicates greater reinforcing efficacy. Values represent difference scores derived from Essential Values coded so that positive numbers indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Alcohol Demand: Essential Value
|
-.18 index
Standard Deviation .25
|
-.072 index
Standard Deviation .18
|
-.24 index
Standard Deviation .22
|
-.073 index
Standard Deviation .28
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in intensity of cannabis demand, assessed using the Marijuana Purchase Task. Intensity reflects the number of joints that would hypothetically be consumed if they were free. Values represent difference scores derived from log-transformed intensity values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Cannabis Demand: Intensity
|
-.019 (log)joints
Standard Deviation .28
|
.12 (log)joints
Standard Deviation .39
|
-.070 (log)joints
Standard Deviation .31
|
-.10 (log)joints
Standard Deviation .54
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in breakpoint of cannabis demand, assessed using the Marijuana Purchase Task. Breakpoint indicates the joint price at which participants report no cannabis consumption. Values represent difference scores derived from breakpoint values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Cannabis Demand: Breakpoint
|
.40 dollars/joint
Standard Deviation 1.78
|
-.14 dollars/joint
Standard Deviation 1.97
|
-.36 dollars/joint
Standard Deviation 1.88
|
-.80 dollars/joint
Standard Deviation 1.59
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in Omax, assessed using the Marijuana Purchase Task. Omax reflects the highest total amount that a participant would spend on cannabis. Values represent difference scores derived from log-transformed Omax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Cannabis Demand: Omax
|
.019 (log)dollars
Standard Deviation .45
|
-.010 (log)dollars
Standard Deviation .20
|
-.001 (log)dollars
Standard Deviation .26
|
-.10 (log)dollars
Standard Deviation .40
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in Pmax, assessed using the Marijuana Purchase Task. Pmax reflects the price point at which demand for cannabis becomes elastic (i.e., declines in response to increasing price). Values represent difference scores derived from log-transformed Pmax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Cannabis Demand: Pmax
|
.0005 log(dollars/joint)
Standard Deviation .22
|
-.043 log(dollars/joint)
Standard Deviation .21
|
.014 log(dollars/joint)
Standard Deviation .24
|
-.10 log(dollars/joint)
Standard Deviation .31
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in Essential Value, assessed using the Marijuana Purchase Task. Essential Value represents the reinforcing efficacy of cannabis, such that higher Essential Value indicates greater reinforcing efficacy. Values represent difference scores derived from Essential Values coded so that positive numbers indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Cannabis Demand: Essential Value
|
-.061 index
Standard Deviation .23
|
.059 index
Standard Deviation .23
|
-.032 index
Standard Deviation .162
|
.15 index
Standard Deviation .27
|
PRIMARY outcome
Timeframe: 48 hours after exerciseChanges in intensity of alcohol demand, assessed using the Alcohol Purchase Task. Intensity reflects the number of drinks that would hypothetically be consumed if they were free. Values represent difference scores derived from log-transformed number of drinks coded so that positive values indicate an increase in the demand index from baseline to follow-up.
Outcome measures
| Measure |
Delayed Onset Muscle Soreness Induction (Women)
n=15 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Women)
n=14 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
Eccentric Biceps Flexion: Muscle lengthening biceps exercise
|
Sham Delayed Onset Muscle Soreness Induction (Men)
n=11 Participants
Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
Concentric Biceps Flexion: Muscle shortening biceps exercise
|
|---|---|---|---|---|
|
Alcohol Demand: Intensity
|
-.094 log(drinks)
Standard Deviation .295
|
.047 log(drinks)
Standard Deviation .15
|
.0958 log(drinks)
Standard Deviation .285
|
-.07 log(drinks)
Standard Deviation .33
|
Adverse Events
Delayed Onset Muscle Soreness Induction
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Sham Delayed Onset Muscle Soreness Induction
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Jeff Boissoneault, PhD
University of Florida Department of Clinical and Health Psychology
Phone: 352-273-6200
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place